Every earnings call for RUBICON — management tone, guidance, KPIs and promise tracking, quarter by quarter.
RUBICON · 3 transcripts · Healthcare · latest Q4 FY26Rubicon Research Limited has 3 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Revenue 5140 million (+44% YoY); Operating EBITDA 1190 million (+64% YoY); PAT 768 million (+112% YoY). Q4 FY26 Revenue of ₹5,140 million, up 44% YoY.
Read full transcript & analysisRevenue ₹476 cr (+52% YoY); EBITDA ₹112 cr (+59% YoY); PAT ₹73 cr (+91% YoY). Revenue for Q3 FY26 was INR476 crores, marking a 52% year-on-year growth.
Read full transcript & analysisEBITDA Margin 22.9%; Gross Margin 68.7%. Revenue grew by 39% YoY, driven by new launches and growth in existing products.
Read full transcript & analysis